Zurich-Schlieren, Switzerland, February 11, 2020. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that Silke Gillessen, one of the world’s leading experts in genitourinary oncology, will present new data from Proclarix in combination with MRI for improved prostate cancer diagnosis to be showcased at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium to be held in San Francisco, California, as follows:
Poster Session A: Prostate Cancer – The Moscone West Building: Level 1, West Hall – Thursday February 13, 2020, 11:30 AM-1:00 PM; 5:30 PM-6:30 PM (local Pacific Time).
Abstract Perm ID: 278
Abstract Title: Evaluation of Proclarix, a prostate cancer risk score, used together with magnetic resonance imaging for the diagnosis of clinically significant prostate cancer.
Presenter: Silke Gillessen, Head Medical Oncology Department / Medical and Scientific Director of Oncology Institute of Southern Switzerland (IOSI)
About Proclarix
Proclarix® is a next generation blood test for prostate cancer. It is non-invasive, thus a diagnosis can be performed without the risk, pain or costs of tissue biopsies. The analysis is fast and saves time by using the same blood sample as PSA testing. Proclarix is precise and reliably identifies high-grade prostate cancer. It will be easily accessible as it can be performed at any local laboratory.
About Proteomedix
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnostics. The company has identified novel biomarker signatures with utility in prostate cancer diagnostics, prognostics and therapy management. Their lead product Proclarix® is a blood based prostate cancer test panel and risk score and will be introduced to the market early 2020. Proteomedix is located in the Biotechnopark of Zurich-Schlieren, Switzerland.
For more information, visit www.proteomedix.com.
For further details, please contact:
Helge Lubenow, CEO
Ralph Schiess, CSO
Unsubscribe:
If you wish to be removed from the distribution list, please unsubscribe here: